Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.
作者信息
Zhang Tongtong, Zhou Haixia, Xu Mingzhu, Qian Chongsheng, Sun Aining, Wu Depei, Xue Shengli
机构信息
Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215000, China.
出版信息
Ann Hematol. 2023 Apr;102(4):973-975. doi: 10.1007/s00277-023-05110-y. Epub 2023 Feb 6.
PMID:36745193
Abstract
摘要
Zotero 插件